文献速递白血病

RERISE 3期研究长期数据:radotinib 与伊马替尼一线治疗慢性期慢性髓性白血病对比

Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
PubMed 文献 · Br J Haematol · 2020-02-03

RERISE 3期研究显示,新诊断慢性期慢性髓性白血病患者接受 radotinib 300 mg 每日两次(n=79)或 400 mg 每日两次(n=81)治疗,12个月时主要分子学反应(MMR)率显著高于伊马替尼 400 mg 每日一次(n=81)。随访≥48个月,radotinib 300 mg 组 MMR 率86%、400 mg 组83%,伊马替尼组75%。

要点

  • 随访≥48个月,radotinib 300 mg 组 MMR 率86%、400 mg 组83%,均高于伊马替尼组75%。
  • 48个月总生存率和无进展生存率三组间无显著差异,安全性特征与既往报告一致。

核心结论

  • radotinib 在≥48个月随访中持续显示稳健的深层分子学反应,提示可能实现无治疗缓解。

研究设计与样本

  • RERISE 为3期研究,纳入新诊断慢性期慢性髓性白血病患者,radotinib 300 mg 每日两次(n=79)、400 mg 每日两次(n=81)对比伊马替尼 400 mg 每日一次(n=81)。

主要发现

  • 随访≥48个月,radotinib 300 mg 组 MMR 率86%、400 mg 组83%,伊马替尼组75%。
  • 48个月估计总生存率和无进展生存率:伊马替尼组94%和94%,radotinib 300 mg 组99%和97%,400 mg 组95%和93%,组间无显著差异。
  • 安全性特征与既往报告一致,大多数不良事件发生在12个月内。

临床怎么用

  • radotinib 可作为新诊断慢性期慢性髓性白血病的一线治疗选择之一,其深层分子学反应率高于伊马替尼且治疗失败率更低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice-daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than with once-daily imatinib 400 mg (n = 81) after 12 months. With ≥48 months' follow-up, MMR was higher with radotinib 300 mg (86%) or 400 mg (83%) than with imatinib (75%). Among patients with BCR-ABL1 ≤ 10% at three months, MMR and molecular response 4·5 (MR4·5 ) were achieved within 48 months by more radotinib-treated patients (300 mg: 84% and 52%, respectively; 400 mg: 74% and 44%, respectively) than imatinib-treated patients (71% and 44%, respectively). Estimated overall and progression-free survival rates at 48 months were not significantly different between imatinib (94% and 94%, respectively) and radotinib 300 mg (99% and 97%, respectively) or 400 mg (95% and 93%, respectively). The treatment failure rate was significantly higher with imatinib (19%) than with radotinib 300 mg (6%; P = 0·0197) or 400 mg (5%; P = 0·0072). Safety profiles were consistent with previous reports; most adverse events occurred within 12 months. Radotinib continues to demonstrate robust, deep molecular responses, suggesting that treatment-free remission may be attainable.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Do YR, Kwak JY, Kim JA, et al. Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). Br J Haematol. 2020. PMID: 32012231. doi:10.1111/bjh.16381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。